DE1902227A1 - Arzneimittel zur psychotherapeutischen Anwendung und Verfahren zu seiner Herstellung - Google Patents
Arzneimittel zur psychotherapeutischen Anwendung und Verfahren zu seiner HerstellungInfo
- Publication number
- DE1902227A1 DE1902227A1 DE19691902227 DE1902227A DE1902227A1 DE 1902227 A1 DE1902227 A1 DE 1902227A1 DE 19691902227 DE19691902227 DE 19691902227 DE 1902227 A DE1902227 A DE 1902227A DE 1902227 A1 DE1902227 A1 DE 1902227A1
- Authority
- DE
- Germany
- Prior art keywords
- psychotherapeutic
- patient
- medicines
- content
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims description 13
- 238000000034 method Methods 0.000 title claims description 4
- 229940079593 drug Drugs 0.000 title claims description 3
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 241001246918 Tabernanthe iboga Species 0.000 claims description 11
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 6
- VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 claims description 5
- 229930013930 alkaloid Natural products 0.000 claims description 5
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 5
- HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 claims description 5
- OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 claims description 5
- AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 229940025084 amphetamine Drugs 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 239000001294 propane Substances 0.000 claims description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 1
- FWFGVMYFCODZRD-UHFFFAOYSA-N oxidanium;hydrogen sulfate Chemical compound O.OS(O)(=O)=O FWFGVMYFCODZRD-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 10
- 208000019901 Anxiety disease Diseases 0.000 description 8
- 230000036506 anxiety Effects 0.000 description 7
- 230000015654 memory Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- KDBZAQNCKQNPQB-UHFFFAOYSA-N 1,1,1-trimethoxy-3-phenylpropan-2-amine Chemical compound COC(C(N)CC1=CC=CC=C1)(OC)OC KDBZAQNCKQNPQB-UHFFFAOYSA-N 0.000 description 1
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 description 1
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 1
- NGBBVGZWCFBOGO-UHFFFAOYSA-N 3,4-Methylenedioxyamphetamine Chemical compound CC(N)CC1=CC=C2OCOC2=C1 NGBBVGZWCFBOGO-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- RRIRDPSOCUCGBV-UHFFFAOYSA-N methylenedioxyphenethylamine Chemical compound NCCC1=CC=C2OCOC2=C1 RRIRDPSOCUCGBV-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR138081A FR7131M (en, 2012) | 1968-01-31 | 1968-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1902227A1 true DE1902227A1 (de) | 1969-09-04 |
Family
ID=8645336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691902227 Pending DE1902227A1 (de) | 1968-01-31 | 1969-01-17 | Arzneimittel zur psychotherapeutischen Anwendung und Verfahren zu seiner Herstellung |
Country Status (5)
| Country | Link |
|---|---|
| BE (1) | BE726760A (en, 2012) |
| CA (1) | CA939266A (en, 2012) |
| DE (1) | DE1902227A1 (en, 2012) |
| FR (1) | FR7131M (en, 2012) |
| GB (1) | GB1256914A (en, 2012) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4857523A (en) * | 1988-07-18 | 1989-08-15 | Nda International, Inc. | Rapid method for attenuating the alcohol dependency syndrome |
| US9561233B2 (en) | 2014-03-13 | 2017-02-07 | Demerx, Inc. | Use of ibogaine for the treatment of pain |
| US9592239B2 (en) | 2014-09-12 | 2017-03-14 | Demerx, Inc. | Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI874163L (fi) * | 1986-09-26 | 1988-03-27 | Mitsui Toatsu Chemicals | Katekolderivat samt preparat innehaollande desamma foer haemmande och botande av regressiva sjukdomar i det centrala nervsystemet. |
| US5214034A (en) * | 1986-09-26 | 1993-05-25 | Mitsui Toatsu Chemicals, Incorporated | Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system containing the same |
| US5290793A (en) * | 1989-09-12 | 1994-03-01 | Mitsui Toatsu Chemicals, Incorporated | Dihydrocaffeic acid derivatives and pharmaceutical preparation containing same |
| US5152994A (en) * | 1990-05-31 | 1992-10-06 | Lotsof Howard S | Rapid method for interrupting or attenuating poly-drug dependency syndromes |
| US7220737B1 (en) | 1997-09-04 | 2007-05-22 | Novoneuron, Inc | Noribogaine in the treatment of pain and drug addiction |
| ES2395268T3 (es) | 1997-09-04 | 2013-02-11 | Demerx, Inc. | Noribogaína para el tratamiento del dolor y la drogadicción |
| JP2004530666A (ja) * | 2001-03-29 | 2004-10-07 | エモリー ユニバーシティ | 学習または条件付けのエンハンサーを用いる精神療法の急性薬理学的増強 |
| US8765737B1 (en) | 2010-05-11 | 2014-07-01 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
| US9394294B2 (en) | 2010-05-11 | 2016-07-19 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
| US8362007B1 (en) | 2010-05-11 | 2013-01-29 | Demerx, Inc. | Substituted noribogaine |
| US8802832B2 (en) | 2010-06-22 | 2014-08-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| US8637648B1 (en) | 2010-06-22 | 2014-01-28 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| US9586954B2 (en) | 2010-06-22 | 2017-03-07 | Demerx, Inc. | N-substituted noribogaine prodrugs |
| US8741891B1 (en) | 2010-06-22 | 2014-06-03 | Demerx, Inc. | N-substituted noribogaine prodrugs |
| EP2595632A1 (en) | 2010-07-23 | 2013-05-29 | DemeRx, Inc. | Noribogaine compositions |
| EP2481740B1 (en) | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
| US9617274B1 (en) | 2011-08-26 | 2017-04-11 | Demerx, Inc. | Synthetic noribogaine |
| WO2013085922A1 (en) | 2011-12-09 | 2013-06-13 | Demerx, Inc. | Phosphate esters of noribogaine |
| US9150584B2 (en) | 2012-01-25 | 2015-10-06 | Demerx, Inc. | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
| EP2807168A4 (en) | 2012-01-25 | 2015-10-14 | Demerx Inc | SYNTHETIC VOACANGINE |
| US9045481B2 (en) | 2012-12-20 | 2015-06-02 | Demerx, Inc. | Substituted noribogaine |
| US8940728B2 (en) | 2012-12-20 | 2015-01-27 | Demerx, Inc. | Substituted noribogaine |
| JP2016508979A (ja) | 2012-12-20 | 2016-03-24 | デメレックス， インコーポレイテッド | 置換ノルイボガイン |
| US9550789B2 (en) | 2014-06-18 | 2017-01-24 | Demerx, Inc. | Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them |
-
1968
- 1968-01-31 FR FR138081A patent/FR7131M/fr not_active Expired
-
1969
- 1969-01-10 BE BE726760D patent/BE726760A/xx unknown
- 1969-01-17 DE DE19691902227 patent/DE1902227A1/de active Pending
- 1969-01-29 CA CA41495A patent/CA939266A/en not_active Expired
- 1969-01-30 GB GB1256914D patent/GB1256914A/en not_active Expired
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4857523A (en) * | 1988-07-18 | 1989-08-15 | Nda International, Inc. | Rapid method for attenuating the alcohol dependency syndrome |
| US9561233B2 (en) | 2014-03-13 | 2017-02-07 | Demerx, Inc. | Use of ibogaine for the treatment of pain |
| US9592239B2 (en) | 2014-09-12 | 2017-03-14 | Demerx, Inc. | Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake |
| US11077118B2 (en) | 2014-09-12 | 2021-08-03 | Demerx, Inc. | Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake |
Also Published As
| Publication number | Publication date |
|---|---|
| CA939266A (en) | 1974-01-01 |
| BE726760A (en, 2012) | 1969-06-16 |
| GB1256914A (en, 2012) | 1971-12-15 |
| FR7131M (en, 2012) | 1969-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1902227A1 (de) | Arzneimittel zur psychotherapeutischen Anwendung und Verfahren zu seiner Herstellung | |
| DE69535607T2 (de) | Zusammensetzung enthaltend Stickstoffoxid-donatoren und Methode zur Behandlung analer Krankheiten | |
| DE3705151A1 (de) | Warzenmittel | |
| DE2856393A1 (de) | Mittel zur behandlung des zentralnervensystems | |
| DE3011437A1 (de) | Pharmazeutisches mittel zur heilung von entzuendlichen und/oder degenerativen und/oder atrophischen schleimhauterkrankungen | |
| DE69419854T2 (de) | Arzneimittelzusammensetzung zur Prophylaxe und Behandlung vorzeitigen Samenergusses | |
| DE4214953A1 (de) | Arzneimittel zur Erhöhung des Testosteronspiegels | |
| DE69110781T2 (de) | Selbstklebendes Matrixsystem für transdermal gesteuerte Abgabe von Piribedil. | |
| DE2359128A1 (de) | Arzneimittel auf basis von lisurid und dessen physiologisch vertraeglichen salzen | |
| DE2758549A1 (de) | Pharmazeutische zubereitung | |
| DE69030584T2 (de) | Verfahren sowie zusammensetzungen zur behandlung mit vitaminmineral | |
| DE19726871C1 (de) | Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe | |
| DE2720420A1 (de) | Wirkstoffkombination gegen sonnenerythem und diese enthaltendes arzneimittel | |
| DE3519736C2 (de) | Mittel zur Behandlung von Rheuma und Polyarthritis | |
| DE60024408T2 (de) | Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen | |
| DE10238161A1 (de) | Mineralstoff-Ampulle für die mucosale und topische Wirkstoffapplikation | |
| DE3447572A1 (de) | Mittel zur regenerierung und staerkung tierischer und menschlicher organismen koerpereigener abwehrkraefte und der haut sowie zu deren schutz aus aloe-wirkstoffen | |
| DE1617508C3 (de) | Antidepressive Mittel | |
| DE2551962C3 (de) | Verwendung eines Extraktes aus verschiedenen Spezies von Helleborus | |
| DE3023396C2 (de) | Arzneimittel zur intravenösen Krebstherapie | |
| DE2830044A1 (de) | Pharmazeutisches praeparat zur behandlung von schlafstoerungen | |
| EP0002803B1 (de) | Cis-(3,3,5)-Trimethylcyclohexanol zur Verwendung bei der Behandlung von Galleleiden | |
| DE2015877A1 (de) | Arzneimittel | |
| DE69524949T2 (de) | Eisen-Chelatierformulierung und Verfahren zu ihrer Herstellung | |
| AT516952B1 (de) | Arzneimittel |